165 related articles for article (PubMed ID: 30448319)
21. Expression and solubilization of insect cell-based rabies virus glycoprotein and assessment of its immunogenicity and protective efficacy in mice.
Ramya R; Mohana Subramanian B; Sivakumar V; Senthilkumar RL; Sambasiva Rao KR; Srinivasan VA
Clin Vaccine Immunol; 2011 Oct; 18(10):1673-9. PubMed ID: 21813661
[TBL] [Abstract][Full Text] [Related]
22. Multicenter comparative study of a new ELISA, PLATELIA RABIES II, for the detection and titration of anti-rabies glycoprotein antibodies and comparison with the rapid fluorescent focus inhibition test (RFFIT) on human samples from vaccinated and non-vaccinated people.
Feyssaguet M; Dacheux L; Audry L; Compoint A; Morize JL; Blanchard I; Bourhy H
Vaccine; 2007 Mar; 25(12):2244-51. PubMed ID: 17224214
[TBL] [Abstract][Full Text] [Related]
23. Glycoprotein from street rabies virus BD06 induces early and robust immune responses when expressed from a non-replicative adenovirus recombinant.
Wang S; Sun C; Zhang S; Zhang X; Liu Y; Wang Y; Zhang F; Wu X; Hu R
Arch Virol; 2015 Sep; 160(9):2315-23. PubMed ID: 26143474
[TBL] [Abstract][Full Text] [Related]
24. Construction and immunogenicity of a recombinant pseudotype baculovirus expressing the glycoprotein of rabies virus in mice.
Huang H; Xiao S; Qin J; Jiang Y; Yang S; Li T; Gao Y; Li Z; Li T; Su X; Ruan Y; Xu F; Wang H; Chen H; Xia X
Arch Virol; 2011 May; 156(5):753-8. PubMed ID: 21221673
[TBL] [Abstract][Full Text] [Related]
25. A relevant in vitro ELISA test in alternative to the in vivo NIH test for human rabies vaccine batch release.
Gibert R; Alberti M; Poirier B; Jallet C; Tordo N; Morgeaux S
Vaccine; 2013 Dec; 31(50):6022-9. PubMed ID: 24161572
[TBL] [Abstract][Full Text] [Related]
26. Standardization of an enzyme immunoassay for the in vitro potency assay of inactivated tissue culture rabies vaccines: determination of the rabies virus glycoprotein with polyclonal antisera.
Thraenhart O; Ramakrishnan K
J Biol Stand; 1989 Oct; 17(4):291-309. PubMed ID: 2613705
[TBL] [Abstract][Full Text] [Related]
27. Enhancing comparative rabies DNA vaccine effectiveness through glycoprotein gene modifications.
Osinubi MO; Wu X; Franka R; Niezgoda M; Nok AJ; Ogunkoya AB; Rupprecht CE
Vaccine; 2009 Nov; 27(51):7214-8. PubMed ID: 19925956
[TBL] [Abstract][Full Text] [Related]
28. Rabies vaccine potency control: comparison of ELISA systems for antigenicity testing.
Rooijakkers EJ; Uittenbogaard JP; Groen J; Osterhaus AD
J Virol Methods; 1996 Apr; 58(1-2):111-9. PubMed ID: 8783156
[TBL] [Abstract][Full Text] [Related]
29. In vitro potency tests: challenges encountered during method development.
Yomayuza CL; Thiel HJ; König M
Dev Biol (Basel); 2012; 134():93-100. PubMed ID: 22888600
[TBL] [Abstract][Full Text] [Related]
30. Rabies virus-like particles expressed in HEK293 cells.
Fontana D; Kratje R; Etcheverrigaray M; Prieto C
Vaccine; 2014 May; 32(24):2799-804. PubMed ID: 24631077
[TBL] [Abstract][Full Text] [Related]
31. Competitive ELISA using a rabies glycoprotein-transformed cell line to semi-quantify rabies neutralizing-related antibodies in dogs.
Zhang S; Liu Y; Zhang F; Hu R
Vaccine; 2009 Mar; 27(15):2108-13. PubMed ID: 19356613
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of SURE RAB™, an inactivated cell culture derived rabies vaccine: A comparative, phase III clinical trial.
Kakar A; Gogia A; Solanki SK; Jadiya A; Singh D
Indian J Med Microbiol; 2021 Jan; 39(1):63-66. PubMed ID: 33526271
[TBL] [Abstract][Full Text] [Related]
33. [Immune response of mice to replication-defective recombinant adenovirus containing glycoprotein gene of rabies virus 3aG strain].
Li W; Zhang Y; Wang S
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Mar; 15(1):61-5. PubMed ID: 12526306
[TBL] [Abstract][Full Text] [Related]
34. Development of a relative potency test using ELISA for human rabies vaccines.
Wang Z; Sun Y; Wu X; Carroll DS; Lv W; You L; Ji Y; Shi J; Yan J; Xu G; Meng S
Biologicals; 2018 Sep; 55():59-62. PubMed ID: 29970288
[TBL] [Abstract][Full Text] [Related]
35. Rabies virus glycoprotein serology ELISA for measurement of neutralizing antibodies in sera of vaccinated human subjects.
Zhao R; Yu P; Shan Y; Thirumeni N; Li M; Lv Y; Li J; Ren W; Huang L; Wei J; Sun Y; Zhu W; Sun L
Vaccine; 2019 Sep; 37(41):6060-6067. PubMed ID: 31471146
[TBL] [Abstract][Full Text] [Related]
36. Negative effects of a disulfide bond mismatch in anti-rabies G protein single-chain antibody variable fragment FV57.
Duan Y; Gu T; Zhang X; Jiang C; Yuan R; Li Z; Wang D; Chen X; Wu C; Chen Y; Wu Y; Kong W
Mol Immunol; 2014 Jun; 59(2):136-41. PubMed ID: 24598312
[TBL] [Abstract][Full Text] [Related]
37. A sindbis virus replicon-based DNA vaccine encoding the rabies virus glycoprotein elicits immune responses and complete protection in mice from lethal challenge.
Saxena S; Dahiya SS; Sonwane AA; Patel CL; Saini M; Rai A; Gupta PK
Vaccine; 2008 Dec; 26(51):6592-601. PubMed ID: 18848857
[TBL] [Abstract][Full Text] [Related]
38. Structural and functional studies on a unique linear neutralizing antigenic site (G5) of the rabies virus glycoprotein.
van der Heijden RW; Langedijk JP; Groen J; UytdeHaag FG; Meloen RH; Osterhaus AD
J Gen Virol; 1993 Aug; 74 ( Pt 8)():1539-45. PubMed ID: 7688410
[TBL] [Abstract][Full Text] [Related]
39. In Vitro ELISA Test to Evaluate Rabies Vaccine Potency.
Jallet C; Tordo N
J Vis Exp; 2020 May; (159):. PubMed ID: 32449742
[TBL] [Abstract][Full Text] [Related]
40. Possibility of Immediate Introduction of a Single-Dose Antibody Induction Test as a Refinement of the NIH Test for Inactivated Rabies Vaccine Potency Determination.
Stankov S; Obradović N; Vujin D; Vranješ N
Viral Immunol; 2020 Jun; 33(5):367-377. PubMed ID: 32159457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
